Related Experiment Video

Updated: Aug 23, 2025

Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia
07:46

Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia

Published on: May 9, 2013

29.3K

The BE COOL Treatments (Batroxobin, oxygEn, Conditioning, and cOOLing): Emerging Adjunct Therapies for Ischemic

Siying Song1,2,3, Hao Wu4, Xunming Ji1,2,3

  • 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Journal of Clinical Medicine
|October 27, 2022
PubMed

Insights

Novel BE COOL treatments, combining batroxobin, oxygen, conditioning, and cooling, show promise for neuroprotection in ischemic cerebrovascular disease (ICD). These therapies aim to improve perfusion and preserve brain tissue, addressing high recurrence rates of acute ischemic stroke and cerebral venous sinus thrombosis.

Area of Science:

  • Neurology
  • Vascular Medicine
  • Neuroprotection

Background:

  • Ischemic cerebrovascular disease (ICD) is a leading cause of neurological disability globally.
  • Current treatments for acute ischemic stroke (AIS) and cerebral venous sinus thrombosis (CVST) have high recurrence rates.
  • Pathogenesis of arterial and venous ischemia may be linked via reduced cerebral perfusion.

Purpose of the Study:

  • To review the neuroprotective effects of novel treatments for ICD.
  • To analyze the clinical application of the BE COOL (Batroxobin, oxygEn, Conditioning, cOOLing) therapeutic strategy.
  • To explore potential improvements in managing ischemic cerebrovascular disease.

Main Methods:

  • Review of existing literature on ICD and potential neuroprotective agents.
  • Analysis of the 'BE COOL' treatment components: Batroxobin, oxygen, conditioning, and cooling.
  • Discussion of the translational potential and clinical application of these novel therapies.

Main Results:

  • The BE COOL treatments demonstrate potential neuroprotective effects.
  • Combination therapy may enhance perfusion recovery and reduce ischemic injury.
  • These novel interventions offer a promising approach beyond current guideline-based therapies.

Conclusions:

  • The BE COOL treatment combination presents a promising strategy for preserving ischemic brain tissue.
  • Further clinical investigation is warranted to validate the efficacy of these novel ICD interventions.
  • Addressing both arterial and venous components of ICD may improve patient outcomes.

Keywords:
batroxobinhypothermiaischemic cerebrovascular diseasenormobaric hyperoxia (NBO)remote ischemic conditioning (RIC)

More Related Videos

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia10:13

Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia

Published on: July 31, 2017

7.5K
Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.1K

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
19
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
305